Infinera Corporation (Nasdaq:INFN) unveiled the DTN-X, the first multi-terabit packet-optical transport (P-OTN) network platform based on groundbreaking 500 Gb/s Photonic Integrated Circuits (PICs), and designed for global service providers facing increasing demands for bandwidth driven by video, mobile and cloud-based services. The DTN-X is purpose-built to integrate switching with DWDM without trade-offs in capacity. The architecture of the DTN-X extends the ease of use and reliability of Infinera’s successful DTN in a new multi-terabit platform that scales for the future, is simple to operate and efficiently reduces the number of elements in the network.
Infinera Corporation provides optical networking systems based on photonic integration technology in the United States.
Radvision Ltd. (Nasdaq:RVSN), a leading technology and end-to-end solution provider for unified visual communications, announced the interoperability of both the SCOPIA Elite MCU Series and SCOPIA iVIEW Management Suite with BroadSoft’s BroadWorks® voice application server. The combination of SCOPIA video conferencing and telepresence solutions with BroadWorks enables service providers to incorporate SIP-based virtualized and hosted visual communications as part of their unified communications (UC) platforms.
RADVISION Ltd. engages in the design, development, and supply of products and technology that enable real-time voice, video and data communications over packet and mobile third generation (3G) networks, including the Internet and other networks based on the Internet Protocol (IP).
Cleantech Transit, Inc. (CLNO)
The use of biomass can be environmentally friendly because the biological mass is reduced, recycled and then re-used. Innovations and ideas in which biomass can be used are continually being invented. One such way is the production of ethanol, a liquid alcohol fuel. Ethanol can be used in special types of cars that have been manufactured to accept alcohol fuels instead of petrol. This innovation helps reduce our dependence on oil. The use of biomass can help reduce Global Warming. Plants use and store carbon dioxide (CO2) when they grow. When it burns or decomposes, it releases the CO2. Replanting plants, crops or trees etc. ensures that the C02 is reused. If the plants are not replanted the biomass will disrupt the natural carbon equilibrium and thus continue to contribute towards Global Warming.
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced a clinical trial update on its lead program, NeuVax(TM) (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin(R)). RXi received official notification from the U.S. Food and Drug Administration (FDA) that the Chemistry, Manufacturing, and Controls (CMC) partial clinical hold has been lifted. RXi has satisfied all requirements specified by the FDA and has initiated a clinical trial material manufacturing plan to remain on schedule to meet the planned trial start date.
RXi Pharmaceuticals Corporation, a biotechnology company, engages in discovering, developing, and commercializing innovative therapies addressing unmet medical needs using targeted bio therapeutics.
No comments:
Post a Comment